Prof. Dr. med. Andreas Ramming

Professur für Immunologie der Organschädigung Medizinische Fakultät

DYNAMIC CHANGES IN O-GLCNACYLATION REGULATE OSTEOCLAST DIFFERENTIATION AND BONE LOSS IN ARTHRITIS (2021) Chen CW, Li YN, Trinh MT, Honglin Z, Matei AE, Ding X, Tran Manh C, et al. Conference contribution 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Conference contribution LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS (2021) Kreuter M, Bonella F, Kathrin K, Henes J, Siegert E, Riemekasten G, Blank N, et al. Conference contribution PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES ARE OVERREPRESENTED IN LOW-FREQUENCY VIRAL SYMPTOM CLUSTERS (2021) Tascilar K, Simon D, Krönke G, Kleyer A, Ramming A, Atreya R, Tenbusch M, et al. Conference contribution NCOA3 AMPLIFIES PROFIBROTIC TRANSCRIPTIONAL PROGRAMS IN SYSTEMIC SCLEROSIS (2021) Dees C, Pötter S, Fuchs M, Bergmann C, Matei AE, Györfi AH, Soare A, et al. Conference contribution Matricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease (2021) Regensburger D, Tenkerian C, Pürzer V, Schmid B, Wohlfahrt T, Stolzer I, Lopez Posadas R, et al. Journal article SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases (2021) Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, Meder C, et al. Journal article Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights (2021) Raimondo MG, Biggioggero M, Coletto LA, Ramming A, Caporali R, Favalli EG Journal article 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study (2021) Bergmann C, Distler J, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei AE, et al. Journal article Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab (2021) Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Journal article